Subsequently, a series of small‐molecule TKIs targeting specific oncogenic drivers, including ALK, ROS1, KRAS, BRAF, MET, and NTRK, were developed and approved as the preferred treatments for advanced NSCLC.6 The gene discussed is ROS1; the disease is non-small cell lung carcinoma.